Literature DB >> 18444962

The ACE gene I/ D polymorphism is not associated with generalized vitiligo susceptibility in Gujarat population.

Mitesh Dwivedi, Naresh C Laddha, E M Shajil, Bela J Shah, Rasheedunnisa Begum.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18444962     DOI： 10.1111/j.1755-148X.2008.00462.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN： 1755-1471            Impact factor:   4.693


× No keyword cloud information.
  11 in total

1.  Interactome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo.

Authors:  R Dey-Rao; A A Sinha
Journal:  Genes Immun       Date:  2015-11-12       Impact factor: 2.676

2.  An alternative method for genotyping of the ACE I/D polymorphism.

Authors:  Kimberly L Glenn; Zhi-Qiang Du; Joey C Eisenmann; Max F Rothschild
Journal:  Mol Biol Rep       Date:  2008-07-13       Impact factor: 2.316

3.  Update on the genetics characterization of vitiligo.

Authors:  Hani A Al-Shobaili
Journal:  Int J Health Sci (Qassim)       Date:  2011-07

4.  Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP.

Authors:  Stanca A Birlea; Ying Jin; Dorothy C Bennett; Deborah M Herbstman; Margaret R Wallace; Wayne T McCormack; E Helen Kemp; David J Gawkrodger; Anthony P Weetman; Mauro Picardo; Giovanni Leone; Alain Taïeb; Thomas Jouary; Khaled Ezzedine; Nanja van Geel; Jo Lambert; Andreas Overbeck; Pamela R Fain; Richard A Spritz
Journal:  J Invest Dermatol       Date:  2010-11-18       Impact factor: 8.551

5.  Involvement of interferon-gamma genetic variants and intercellular adhesion molecule-1 in onset and progression of generalized vitiligo.

Authors:  Mitesh Dwivedi; Naresh C Laddha; Kriti Shah; Bela J Shah; Rasheedunnisa Begum
Journal:  J Interferon Cytokine Res       Date:  2013-06-18       Impact factor: 2.607

6.  Tumor necrosis factor B (TNFB) genetic variants and its increased expression are associated with vitiligo susceptibility.

Authors:  Naresh C Laddha; Mitesh Dwivedi; Amina R Gani; Mohmmad Shoab Mansuri; Rasheedunnisa Begum
Journal:  PLoS One       Date:  2013-11-27       Impact factor: 3.240

7.  Vitiligo blood transcriptomics provides new insights into disease mechanisms and identifies potential novel therapeutic targets.

Authors:  Rama Dey-Rao; Animesh A Sinha
Journal:  BMC Genomics       Date:  2017-01-28       Impact factor: 3.969

8.  Associations of Angiotensin-Converting Enzyme Gene Insertion/Deletion (ACE Gene I/D) Polymorphism With Vitiligo: An Updated Systematic Review and Meta-Analysis.

Authors:  Mohammad Almohideb
Journal:  Cureus       Date:  2020-05-10

9.  Increased Tumor Necrosis Factor (TNF)-α and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo.

Authors:  Naresh C Laddha; Mitesh Dwivedi; Rasheedunnisa Begum
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

10.  A Comparison of Betamethasone Valerate 0.1% Cream Twice Daily Plus Oral Simvastatin Versus Betamethasone Valerate 0.1% Cream Alone in the Treatment of Vitiligo Patients.

Authors:  Fariba Iraji; Seyed Hossin Banihashemi; Gita Faghihi; Zabihollah Shahmoradi; Nabet Tajmirriahi; Safoura Bokaie Jazi
Journal:  Adv Biomed Res       Date:  2017-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.